Fill Finish Pharmaceutical Contract Manufacturing Market CAGR To Be Around 4.8% by 2035, Due to The Growing Pipeline of Small Molecules| Roots Analysis

According to our latest market report “fill finish pharmaceutical contract manufacturing market, till 2035 by Type of Fill Finish Service Offered, Type of FDF, API Potency, Type of Primary Packaging Container, Scale of Operation, Company Size, Geographical Regions and Leading Players: Industry Trends and Global Forecasts”, the global fill finish pharmaceutical contract manufacturing market size is projected to reach USD 12.1 billion by 2035 from USD 7.2 billion in 2024, growing at a CAGR of 4.8% in the forecast period 2024-2035.

 Fill / finish is the final step in downstream processing of a product, wherein the purified formulation of the small molecules is mixed with the necessary excipients and stabilizers. The product is then formulated and aliquoted into the appropriate dosage forms for clinical use or commercial distribution. These operations are automated and are usually carried out under aseptic conditions. 

However, Owing to the complexities involved in the development of small molecule drugs and lack of sufficient in-house capacity, drug developers prefer to outsource their fill finish operations. Therefore, the pharmaceutical fill finish CMOs are anticipated to contribute significantly in the healthcare domain in the coming years.

Fill Finish Pharmaceutical Contract Manufacturing Market Key Players

Examples of key companies engaged in fill finish pharmaceutical contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include (in alphabetic order) Alcami, Amanta Healthcare, Aurigene Services, Batterjee Pharma, Burrard Pharmaceuticals, Curida, Eriochem, Fresenius Kabi, GlaxoSmithKline, Nextar Chempharma Solutons, Pfizer CentreOne, Plastikon Healthcare, Procaps, Recipharm, ROMMELAG CMO, Sharp Services, Sypharma, Teva Pharmaceuticals and WuXi AppTec. 

Fill Finish Pharmaceutical Contract Manufacturing Market Segments 

Based on the type of fill finish service offered, the market is segmented into aseptic filling, blow-fill-seal and terminal sterilization.

·         The terminal sterilization segment is likely to capture the largest revenue share of close to 45% in the fill finish pharmaceutical contract manufacturing market, in 2024.

·         The aseptic filling segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 5.4% during the forecast period.

Based on the type of FDF, the market is segmented into generic FDF and originator FDF.

·         The originator FDF segment is likely to capture the largest revenue share of close to 55% in the fill finish pharmaceutical contract manufacturing market, in 2024.

·         The generic segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 5.4% during the forecast period.

Based on the type of API potency, the market is segmented into low potent API and high potent API.

·         The low potent API segment is likely to capture the largest revenue share of more than 85% in fill finish pharmaceutical contract manufacturing market, in 2024.

·         The high potent API segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 9% during the forecast period. 

Based on the type of primary packaging container, the market is segmented into ampoules, cartridges, prefilled syringe, vials and other containers.

·        The vials segment is likely to capture the largest revenue share of 50% in the fill finish pharmaceutical contract manufacturing market, in 2024.

·         The other containers segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 7.5% during the forecast period.

Based on the scale of operation, the market is segmented into clinical and commercial scale.

·         The commercial segment is likely to capture the largest revenue share of 95% in the fill finish pharmaceutical contract manufacturing market, in 2024.

·         The clinical segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 7.4% during the forecast period.

Based on the company size, the market is segmented into small and mid-sized companies and large / very large companies.

·         The large / very large companies segment is likely to capture the largest revenue share of 90% in the fill finish pharmaceutical contract manufacturing market, in 2024.

·         The small and mid-sized companies segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 6.9% during the forecast period.

Based on the Regional Insights, the market is segmented North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa

·         Europe dominated the fill finish pharmaceutical contract manufacturing market and is likely to account for the largest revenue share of close to 40% in 2024.

·         In rest of the world, fill finish pharmaceutical contract manufacturing market is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 11% during the forecast period.

Fill Finish Pharmaceutical Contract Manufacturing Market Regional Outlook

Based on the geographical regions, the fill finish pharmaceutical contract manufacturing market can be segmented into five major regions, including North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and rest of the world. Europe is anticipated to capture the majority share of the fill finish pharmaceutical contract manufacturing market in 2024. Further, the fill finish pharmaceutical contract manufacturing industry in rest of the world is accounted to be the fastest-growing segment of the market. This is primarily due to the rising demand for small molecule drugs targeting various diseases. 

Key Report Takeaways

·         Currently, close to 390 CMOs offering fill finish manufacturing services for small molecules are available across the world; majority of the solution providers are based in North America and Europe

·         Owing to the financial prosperity and the cultural norms present in the region, the US has emerged as a hub of the established players and the new entrants in this industry

·         Owing to rising need for small molecule drug products, the fill finish pharmaceutical contract manufacturing market is anticipated to witness an annualized growth of 4.8%, over the next decade

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com